Cargando…
Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
Cancer cachexia is a multifactorial disease that causes continuous skeletal muscle wasting. Thereby, it seems to be a key determinant of cancer‐related death. Although anamorelin, a ghrelin receptor agonist, has been approved in Japan for the treatment of cachexia, few medical treatments for cancer...
Autores principales: | Hanada, Kako, Fukasawa, Kunpei, Hinata, Hiroki, Imai, Shú, Takayama, Kentaro, Hirai, Hideyo, Ohfusa, Rina, Hayashi, Yoshio, Itoh, Fumiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530881/ https://www.ncbi.nlm.nih.gov/pubmed/35849084 http://dx.doi.org/10.1111/cas.15491 |
Ejemplares similares
-
Peptide‐2 from mouse myostatin precursor protein alleviates muscle wasting in cancer‐associated cachexia
por: Ojima, Chiharu, et al.
Publicado: (2020) -
Endothelial-specific depletion of TGF-β signaling affects lymphatic function
por: Fukasawa, Kunpei, et al.
Publicado: (2021) -
Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023) -
Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022) -
Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)